Latest Benzimidazoles Stories

Study at UCSF and Yale finds protease inhibitors are potent, single-day cures for disease in hamsters A drug candidate that is nearing clinical trials against a Latin American parasite is showing additional promise as a cure for hookworm, one of the most widespread and insidious parasites afflicting developing nations, according to a collaborative study at UCSF and Yale University. The drug candidate, known by the scientific name K11777, is under development at UCSF and is targeted to...

RIDGEFIELD, Conn., June 18, 2012 /PRNewswire/ -- A new retrospective sub-analysis of the RE-LY® trial suggested similar rates of peri-procedural bleeding and thromboembolic complications, such as a stroke or systemic embolism, in non-valvular atrial fibrillation (NVAF) patients undergoing a surgical or invasive procedure treated with Pradaxa® (dabigatran etexilate mesylate) capsules 150mg taken twice daily compared to warfarin. The peri-procedural period was defined in this...

RIDGEFIELD, Conn., June 6, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the Pradaxa® (dabigatran etexilate mesylate) capsules prescribing information has been updated to affirm that "PRADAXA 150mg twice daily was superior in reducing ischemic and hemorrhagic strokes relative to warfarin." The update to the "Clinical Studies" section is based on the results of the pivotal RE-LY® trial conducted in 18,000 patients with non-valvular atrial...

EXTON, Pa., June 4, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced the initiation of a Phase 2 program to evaluate maribavir for the treatment of cytomegalovirus infections in transplant recipients. The planned program will consist of two independent Phase 2 clinical studies that will include subjects at different ends of the spectrum of CMV infection or disease, namely those who have asymptomatic CMV, and those who have failed therapy with other anti-CMV...

FORT WORTH, Texas, June 1, 2012 /PRNewswire/ -- A motion was filed on May 30, 2012 with the United States Judicial Panel on Multidistrict Litigation (JPML) petitioning for the creation of a coordinated federal MDL for all cases concerning the anticoagulant drug Pradaxa (dabigatran etexilate mesylate). The motion seeks to transfer pending cases and future claims relating to Pradaxa to the United States District Court for the Southern District of Illinois for consolidation. The United...

In April 2012, MHRA published an article revealing that there is recent epidemiological evidence of an increased risk of fracture with long-term use of PPIs (Proton Pump Inhibitors), including Nexium. Nexium, manufactured by AstraZeneca, is a medication that people take to prevent on-going heartburn. According to court documents, on April 19th, 2011, an Ohio woman, Ginny Begin, filed a lawsuit Texas Southern District Court (case no. 4:2011cv01489) against AstraZeneca, alleging that she...

THE WOODLANDS, Texas, May 15, 2012 /PRNewswire/ -- Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced the introduction of Omeclamox-Pak®, a ten-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg) for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients....

RIDGEFIELD, Conn., May 3, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the launch of the GLORIA(TM)-AF Registry Program, the largest prospective observational study in non-valvular atrial fibrillation (NVAF) planned at this time. With a goal of enrolling 56,000 patients, the registry aims to understand the long-term use of antithrombotic treatments to reduce the risk of stroke in patients with NVAF. GLORIA-AF will follow newly-diagnosed...

RIDGEFIELD, Conn., April 18, 2012 /PRNewswire/ -- A new retrospective sub-analysis of the 18,113 patient RE-LY® trial showed lower rates of intracranial hemorrhage (ICH), including both fatal and traumatic ICH, for Pradaxa® (dabigatran etexilate mesylate) capsules 150mg taken twice daily compared with warfarin. Results of the sub-analysis recently were published online in Stroke: The Journal of the American Heart Association. Intracranial hemorrhage can be a devastating...

On February 8th, 2012 the U.S. FDA issued a warning on drugs called proton pump inhibitors (PPIs) – including Prilosec - that might increase the risk of a type of chronic diarrhea and lead to severe intestinal problems and, in rare cases, death. Prilosec is a proton pump inhibitor (PPI) prescribed to treat acid reflux, stomach ulcers and other conditions. Moreover, in May 2010, the FDA announced that the safety labeling for proton pump inhibitors would be updated to include information...